MADISON, N.J., June 9, 2011 /PRNewswire/ — Quest Diagnostics
Incorporated (NYSE:
DGX), the world’s leading provider of diagnostic testing,
information and services, today announced that its Simplexa™
molecular diagnostic test on the 3M™ Integrated Cycler won a
gold award in the in vitro diagnostics category at the 2011
MDEA awards ceremony yesterday in New York City. Focus Diagnostics,
the infectious disease diagnostics business of Quest Diagnostics,
developed and provides the Simplexa™ line of molecular test
products operating on the 3M Integrated Cycler as part of an
exclusive global collaboration with 3M (MMM).
“Winning the MDEA award underscores our commitment to developing
industry-leading diagnostics that will help physicians more
effectively diagnose, treat and manage their patients,” said Surya
N. Mohapatra, Ph.D., chairman and chief executive officer, Quest
Diagnostics. “We are particularly gratified to share this honor
with our close collaborator 3M, a company which shares our
enthusiasm for developing breakthrough technologies that help
improve patient care.”
The MDEA competition recognizes advances in the design of
medical products. Presented by UBM Canon, MDEA award winners are
selected by an impartial jury on criteria that include design and
engineering features that improve healthcare delivery, innovative
use of materials and components, and functional innovations that
change traditional medical attitudes or practices or offer
significant use-related improvements.
In April 2011, the Simplexa/3M technology won a bronze 2011
Edison Award for new science and medical diagnostic product, based
on criteria that included technological innovation and marketplace
success.
Focus Diagnostics launched the Simplexa molecular product line
in 2009. Simplexa was the first test kit to be FDA cleared for
aiding in the detection and d
‘/>”/>
SOURCE